News articles about Teladoc (NYSE:TDOC) have trended somewhat positive on Friday, according to AlphaOne Sentiment. The research group, a service of Accern, ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teladoc earned a coverage optimism score of 0.21 on AlphaOne’s scale. AlphaOne also gave media headlines about the health services provider an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have impacted Alpha One’s scoring:

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Shares of Teladoc (NYSE TDOC) traded up 1.95% during midday trading on Friday, hitting $34.00. 996,659 shares of the stock were exchanged. The company’s market cap is $1.85 billion. The stock has a 50 day moving average price of $29.48 and a 200-day moving average price of $23.00. Teladoc has a 12 month low of $12.31 and a 12 month high of $34.60.

Teladoc (NYSE:TDOC) last posted its earnings results on Monday, May 8th. The health services provider reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Teladoc had a negative net margin of 53.58% and a negative return on equity of 24.73%. The business had revenue of $42.90 million for the quarter, compared to analysts’ expectations of $42.22 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The business’s revenue for the quarter was up 59.5% compared to the same quarter last year. On average, analysts predict that Teladoc will post ($0.88) EPS for the current year.

Several research firms recently commented on TDOC. Robert W. Baird reiterated an “outperform” rating and issued a $33.00 price target (up previously from $28.00) on shares of Teladoc in a research report on Friday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $40.00 price objective (up previously from $27.00) on shares of Teladoc in a research note on Friday, June 9th. Piper Jaffray Companies raised their price objective on shares of Teladoc from $26.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 11th. Chardan Capital raised their price objective on shares of Teladoc from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Finally, Craig Hallum downgraded shares of Teladoc from a “buy” rating to a “hold” rating and lifted their price target for the company from $28.00 to $32.00 in a research note on Friday, May 12th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $31.31.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/06/16/teladoc-tdoc-earns-daily-news-sentiment-rating-of-0-21-updated-updated-updated.html.

In related news, CEO Jason N. Gorevic sold 19,991 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $32.89, for a total value of $657,503.99. Following the sale, the chief executive officer now directly owns 831,650 shares of the company’s stock, valued at $27,352,968.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 13,389 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $32.89, for a total transaction of $440,364.21. Following the completion of the sale, the chief executive officer now directly owns 831,650 shares in the company, valued at $27,352,968.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 232,480 shares of company stock worth $6,439,354. Corporate insiders own 5.94% of the company’s stock.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.